Review



human il33  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems human il33
    Human Il33, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 88 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+33/Human+IL-33+Antibody/us12594324-380-11-14
    Average 93 stars, based on 88 article reviews
    human il33 - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Incubation:

    Article Title: Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation.
    Article Snippet: .. After 24 h, the cells were fasted in 0.1% bovine serum albumin (BSA) for 4 h. Then, the cells were incubated with fresh complete medium in the presence of recombinant human IL-33 (rhIL-33, R&D Systems) at 0, 10, 50, and 100 ng/mL. .. The proliferation rate based on cell confluence was determined by live cell imaging (10× objective lens) using the IncuCyte ZOOM integrated software (Sartorius, Ann Arbor, MI, USA).

    Article Title: IL-1 receptor accessory protein-inhibiting antibodies and antigen-binding fragments thereof
    Article Snippet: Human IL-33 Induced IFN-γ Release in Human PBMCs: The cells were suspended in Medium RPMI 1640 (Life Technologies cat #M-106-500) with FCS 10%, P/S 1% (both Life Technologies) and recombinant human IL-12 to a final concentration of 0.6 nM (R&D Systems, Cat #219-IL-025) and seeded in 384-well plates (50000 cells/well) in a volume of 30 μl on the assay day. .. 10 μl of the test antibodies were added to the cells and incubated for 30 min. 10 uL of IL-33 was added to the cells in a final concentration of 0.05 nM (human IL-33, R&D Systems cat #3625-IL-010). ..

    Article Title: Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation
    Article Snippet: .. After 24 h, the cells were fasted in 0.1% bovine serum albumin (BSA) for 4 h. Then, the cells were incubated with fresh complete medium in the presence of recombinant human IL-33 (rhIL-33, R&D Systems) at 0, 10, 50, and 100 ng/mL. .. The proliferation rate based on cell confluence was determined by live cell imaging (10× objective lens) using the IncuCyte ZOOM integrated software (Sartorius, Ann Arbor, MI, USA).

    Recombinant:

    Article Title: Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation.
    Article Snippet: .. After 24 h, the cells were fasted in 0.1% bovine serum albumin (BSA) for 4 h. Then, the cells were incubated with fresh complete medium in the presence of recombinant human IL-33 (rhIL-33, R&D Systems) at 0, 10, 50, and 100 ng/mL. .. The proliferation rate based on cell confluence was determined by live cell imaging (10× objective lens) using the IncuCyte ZOOM integrated software (Sartorius, Ann Arbor, MI, USA).

    Article Title: Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation
    Article Snippet: .. After 24 h, the cells were fasted in 0.1% bovine serum albumin (BSA) for 4 h. Then, the cells were incubated with fresh complete medium in the presence of recombinant human IL-33 (rhIL-33, R&D Systems) at 0, 10, 50, and 100 ng/mL. .. The proliferation rate based on cell confluence was determined by live cell imaging (10× objective lens) using the IncuCyte ZOOM integrated software (Sartorius, Ann Arbor, MI, USA).

    Article Title: Humanized anti-IL-1R3 antibodies
    Article Snippet: .. Cells were then stimulated with recombinant human IL-33 (20 ng/mL, RnD systems) for 24 hrs before harvesting supernatants and assaying for IL-8 production (Duoset ELISA, RnD Systems). ..

    Concentration Assay:

    Article Title: IL-1 receptor accessory protein-inhibiting antibodies and antigen-binding fragments thereof
    Article Snippet: Human IL-33 Induced IFN-γ Release in Human PBMCs: The cells were suspended in Medium RPMI 1640 (Life Technologies cat #M-106-500) with FCS 10%, P/S 1% (both Life Technologies) and recombinant human IL-12 to a final concentration of 0.6 nM (R&D Systems, Cat #219-IL-025) and seeded in 384-well plates (50000 cells/well) in a volume of 30 μl on the assay day. .. 10 μl of the test antibodies were added to the cells and incubated for 30 min. 10 uL of IL-33 was added to the cells in a final concentration of 0.05 nM (human IL-33, R&D Systems cat #3625-IL-010). ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Epidermal growth factor receptor controls sex differences in lung type 2 responses to inhaled allergen.
    Article Snippet: Hormonal disruptions are associated with poor asthma control in females, yet how these phenomena are linked remains unknown.. Here, we investigated distinct allergeninduced immune responses between the sexes during maturation.. By 6 weeks of life, female mice exposed to the aeroallergen house dust mite (HDM) from postnatal day 7 exhibited stronger type 2 (T2) immune responses and higher lung interleukin33 (IL33) than males.

    Article Title: A skin isolate of Micrococcus luteus negates the Staphylococcus aureus- induced release of type 2 cytokines from keratinocytes
    Article Snippet: .. To quantify IL-33 and TSLP in NHEK conditioned medium, human IL-33 (R&D systems) and human TSLP (R&D Systems) DuoSet ELISA Kits were used according to manufacturer’s instructions. .. 99.9% Acetone (Fisher Scientific) chilled to -20 ̊C was added to bacterial supernatant at a ratio of 4:1.

    Article Title: Humanized anti-IL-1R3 antibodies
    Article Snippet: .. Cells were then stimulated with recombinant human IL-33 (20 ng/mL, RnD systems) for 24 hrs before harvesting supernatants and assaying for IL-8 production (Duoset ELISA, RnD Systems). ..

    Binding Assay:

    Article Title: Anti-IL-33 antibodies and uses thereof
    Article Snippet: Binding competition between a panel of different anti-IL-33 monoclonal antibodies was determined using a real time, label-free bio-layer interferometry assay on an Octet® HTX biosensor (ForteBio, A Division of Pall Life Sciences). .. To assess whether two antibodies were able to compete with one another for binding to human IL-33, a pre-mix assay format was used where 100 nM of human IL-33 (R&D Systems; #3625-IL-010/CF) was pre-mixed with 500 nM of different anti-IL-33 monoclonal antibodies (subsequently referred to as mAb-2) for at least 2 hours prior to running the binding competition assay. .. Octet biosensors coated with either an anti-mouse Fc polyclonal antibody (Pall ForteBio Corp., #18-5088; subsequently referred as AMC) or with an anti-human Fc polyclonal antibody (Pall ForteBio Corp., #18-5060; subsequently referred as AHC) were first submerged into wells containing 20 μg/mL of individual anti-IL-33 monoclonal antibodies for 3 minutes to capture anti-IL-33 monoclonal antibodies expressed either a with mouse Fc or with a human Fc, respectively (subsequently referred to as mAb-1).

    Bioprocessing:

    Article Title: Anti-IL-33 antibodies and uses thereof
    Article Snippet: Binding competition between a panel of different anti-IL-33 monoclonal antibodies was determined using a real time, label-free bio-layer interferometry assay on an Octet® HTX biosensor (ForteBio, A Division of Pall Life Sciences). .. To assess whether two antibodies were able to compete with one another for binding to human IL-33, a pre-mix assay format was used where 100 nM of human IL-33 (R&D Systems; #3625-IL-010/CF) was pre-mixed with 500 nM of different anti-IL-33 monoclonal antibodies (subsequently referred to as mAb-2) for at least 2 hours prior to running the binding competition assay. .. Octet biosensors coated with either an anti-mouse Fc polyclonal antibody (Pall ForteBio Corp., #18-5088; subsequently referred as AMC) or with an anti-human Fc polyclonal antibody (Pall ForteBio Corp., #18-5060; subsequently referred as AHC) were first submerged into wells containing 20 μg/mL of individual anti-IL-33 monoclonal antibodies for 3 minutes to capture anti-IL-33 monoclonal antibodies expressed either a with mouse Fc or with a human Fc, respectively (subsequently referred to as mAb-1).

    Competitive Binding Assay:

    Article Title: Anti-IL-33 antibodies and uses thereof
    Article Snippet: Binding competition between a panel of different anti-IL-33 monoclonal antibodies was determined using a real time, label-free bio-layer interferometry assay on an Octet® HTX biosensor (ForteBio, A Division of Pall Life Sciences). .. To assess whether two antibodies were able to compete with one another for binding to human IL-33, a pre-mix assay format was used where 100 nM of human IL-33 (R&D Systems; #3625-IL-010/CF) was pre-mixed with 500 nM of different anti-IL-33 monoclonal antibodies (subsequently referred to as mAb-2) for at least 2 hours prior to running the binding competition assay. .. Octet biosensors coated with either an anti-mouse Fc polyclonal antibody (Pall ForteBio Corp., #18-5088; subsequently referred as AMC) or with an anti-human Fc polyclonal antibody (Pall ForteBio Corp., #18-5060; subsequently referred as AHC) were first submerged into wells containing 20 μg/mL of individual anti-IL-33 monoclonal antibodies for 3 minutes to capture anti-IL-33 monoclonal antibodies expressed either a with mouse Fc or with a human Fc, respectively (subsequently referred to as mAb-1).



    Similar Products

    94
    Bio-Techne corporation human il-33 quantikine elisa kit
    Human Il 33 Quantikine Elisa Kit, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+33/Human+IL-33+Quantikine+ELISA+Kit/custom%40d3300b%4042314770
    Average 94 stars, based on 1 article reviews
    human il-33 quantikine elisa kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress human il 33
    Human Il 33, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+33/IL-33%2C+Human/pm42277334-147-6-11
    Average 94 stars, based on 1 article reviews
    human il 33 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress il 33
    Mechanism underlying tumor necrosis factor-like ligand 1A (TL1A)–C-C motif chemokine ligand 8 (CCL8) axis activation in the context of allergic inflammation. (A and B) Expression levels of TL1A induced by different stimuli in human airway epithelial cells or macrophages. (C) TL1A expression in uninduced macrophages, macrophages induced by interleukin 33 <t>(IL-33),</t> and macrophages induced by IL-33 plus interleukin 2 (IL-2). (D and E) Comparison of the expression levels of CCL8 induced by different concentrations of TL1A, quantified using reverse transcription polymerase chain reaction (RT-PCR) or transcriptomic sequencing. The messenger RNA (mRNA) levels of CCL8 after the transfection of TL1A-M plasmids, quantified using RT-PCR (F) or transcriptomic sequencing (G). (H) Death receptor 3 (DR3) knockdown abolished the elevation of CCL8 induced by TL1A stimulation. (I) CCL8 level in CD14 + macrophages treated or not with TL1A. (J) RT-PCR analysis of CCL8 transcript following DR3 small interfering RNA (siRNA) treatment. Representative data from CD14 + cells from a single donor. (K) A schematic for the administration of different signaling pathway inhibitors to investigate the pathways involved in TL1A–CCL8 axis activation (BAY11-7082, a nuclear factor kappa B [NF-κB] inhibitor; LY294002, a phosphoinositide 3-kinase [PI3K inhibitor]; PD98059, an extracellular signal-regulated kinase [ERK] inhibitor; SB203580, a p38 inhibitor; and SP600125, a c-Jun N-terminal kinase [JNK] inhibitor). Data are presented as the mean ± SD of triplicate measurements from at least 3 independent cell culture experiments. For primary human macrophage experiments (I and J), cells were derived from n = 4 healthy donors. * P < 0.05 and ** P < 0.01 compared with the respective groups. All in vitro stimulation and inhibitor treatments were analyzed in a blinded manner.
    Il 33, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+33/IL-33%2C+Human/pmc13062487-208-14-18
    Average 94 stars, based on 1 article reviews
    il 33 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    R&D Systems human il33
    Mechanism underlying tumor necrosis factor-like ligand 1A (TL1A)–C-C motif chemokine ligand 8 (CCL8) axis activation in the context of allergic inflammation. (A and B) Expression levels of TL1A induced by different stimuli in human airway epithelial cells or macrophages. (C) TL1A expression in uninduced macrophages, macrophages induced by interleukin 33 <t>(IL-33),</t> and macrophages induced by IL-33 plus interleukin 2 (IL-2). (D and E) Comparison of the expression levels of CCL8 induced by different concentrations of TL1A, quantified using reverse transcription polymerase chain reaction (RT-PCR) or transcriptomic sequencing. The messenger RNA (mRNA) levels of CCL8 after the transfection of TL1A-M plasmids, quantified using RT-PCR (F) or transcriptomic sequencing (G). (H) Death receptor 3 (DR3) knockdown abolished the elevation of CCL8 induced by TL1A stimulation. (I) CCL8 level in CD14 + macrophages treated or not with TL1A. (J) RT-PCR analysis of CCL8 transcript following DR3 small interfering RNA (siRNA) treatment. Representative data from CD14 + cells from a single donor. (K) A schematic for the administration of different signaling pathway inhibitors to investigate the pathways involved in TL1A–CCL8 axis activation (BAY11-7082, a nuclear factor kappa B [NF-κB] inhibitor; LY294002, a phosphoinositide 3-kinase [PI3K inhibitor]; PD98059, an extracellular signal-regulated kinase [ERK] inhibitor; SB203580, a p38 inhibitor; and SP600125, a c-Jun N-terminal kinase [JNK] inhibitor). Data are presented as the mean ± SD of triplicate measurements from at least 3 independent cell culture experiments. For primary human macrophage experiments (I and J), cells were derived from n = 4 healthy donors. * P < 0.05 and ** P < 0.01 compared with the respective groups. All in vitro stimulation and inhibitor treatments were analyzed in a blinded manner.
    Human Il33, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+33/Human+IL-33+Antibody/us12594324-380-11-14
    Average 93 stars, based on 1 article reviews
    human il33 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    R&D Systems recombinant murine il33
    Mechanism underlying tumor necrosis factor-like ligand 1A (TL1A)–C-C motif chemokine ligand 8 (CCL8) axis activation in the context of allergic inflammation. (A and B) Expression levels of TL1A induced by different stimuli in human airway epithelial cells or macrophages. (C) TL1A expression in uninduced macrophages, macrophages induced by interleukin 33 <t>(IL-33),</t> and macrophages induced by IL-33 plus interleukin 2 (IL-2). (D and E) Comparison of the expression levels of CCL8 induced by different concentrations of TL1A, quantified using reverse transcription polymerase chain reaction (RT-PCR) or transcriptomic sequencing. The messenger RNA (mRNA) levels of CCL8 after the transfection of TL1A-M plasmids, quantified using RT-PCR (F) or transcriptomic sequencing (G). (H) Death receptor 3 (DR3) knockdown abolished the elevation of CCL8 induced by TL1A stimulation. (I) CCL8 level in CD14 + macrophages treated or not with TL1A. (J) RT-PCR analysis of CCL8 transcript following DR3 small interfering RNA (siRNA) treatment. Representative data from CD14 + cells from a single donor. (K) A schematic for the administration of different signaling pathway inhibitors to investigate the pathways involved in TL1A–CCL8 axis activation (BAY11-7082, a nuclear factor kappa B [NF-κB] inhibitor; LY294002, a phosphoinositide 3-kinase [PI3K inhibitor]; PD98059, an extracellular signal-regulated kinase [ERK] inhibitor; SB203580, a p38 inhibitor; and SP600125, a c-Jun N-terminal kinase [JNK] inhibitor). Data are presented as the mean ± SD of triplicate measurements from at least 3 independent cell culture experiments. For primary human macrophage experiments (I and J), cells were derived from n = 4 healthy donors. * P < 0.05 and ** P < 0.01 compared with the respective groups. All in vitro stimulation and inhibitor treatments were analyzed in a blinded manner.
    Recombinant Murine Il33, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+33/Recombinant+Human+IL-33+Protein%2C+CF/us12594324-113-5-11
    Average 94 stars, based on 1 article reviews
    recombinant murine il33 - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    93
    R&D Systems antibody to il33
    Mechanism underlying tumor necrosis factor-like ligand 1A (TL1A)–C-C motif chemokine ligand 8 (CCL8) axis activation in the context of allergic inflammation. (A and B) Expression levels of TL1A induced by different stimuli in human airway epithelial cells or macrophages. (C) TL1A expression in uninduced macrophages, macrophages induced by interleukin 33 <t>(IL-33),</t> and macrophages induced by IL-33 plus interleukin 2 (IL-2). (D and E) Comparison of the expression levels of CCL8 induced by different concentrations of TL1A, quantified using reverse transcription polymerase chain reaction (RT-PCR) or transcriptomic sequencing. The messenger RNA (mRNA) levels of CCL8 after the transfection of TL1A-M plasmids, quantified using RT-PCR (F) or transcriptomic sequencing (G). (H) Death receptor 3 (DR3) knockdown abolished the elevation of CCL8 induced by TL1A stimulation. (I) CCL8 level in CD14 + macrophages treated or not with TL1A. (J) RT-PCR analysis of CCL8 transcript following DR3 small interfering RNA (siRNA) treatment. Representative data from CD14 + cells from a single donor. (K) A schematic for the administration of different signaling pathway inhibitors to investigate the pathways involved in TL1A–CCL8 axis activation (BAY11-7082, a nuclear factor kappa B [NF-κB] inhibitor; LY294002, a phosphoinositide 3-kinase [PI3K inhibitor]; PD98059, an extracellular signal-regulated kinase [ERK] inhibitor; SB203580, a p38 inhibitor; and SP600125, a c-Jun N-terminal kinase [JNK] inhibitor). Data are presented as the mean ± SD of triplicate measurements from at least 3 independent cell culture experiments. For primary human macrophage experiments (I and J), cells were derived from n = 4 healthy donors. * P < 0.05 and ** P < 0.01 compared with the respective groups. All in vitro stimulation and inhibitor treatments were analyzed in a blinded manner.
    Antibody To Il33, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+33/Human+IL-33+Antibody/us12594324-372-1-10
    Average 93 stars, based on 1 article reviews
    antibody to il33 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    94
    R&D Systems human il 33 duoset elisa kit
    A CellChat analysis of human lung snRNA-seq data. B Venn of 47 shared DEGs from four datasets ( GSE159354 , GSE132771 , GSE128033 , GSE122960 ). C Heatmap of 47-gene expression across cell types. D Correlation analysis (Pearson Correlation) of expression of IGFBP5, IL33, MGP, SPRY1, ACKR1 and mechanical stress scores in ECs. E Correlation analysis (Pearson Correlation) of expression of PIEZO1 and IGFBP5, IL33, MGP, SPRY1, ACKR1 in ECs. F Human snRNA-seq UMAP and violin of IL33 distribution and subpopulations. G Bar chart showed expression of IL33 (mean ± SEM) in IPF (n = 7966 cells) vs control (n = 4174 cells). P value was calculated using the two-tailed unpaired t-test. H Violin of IL33 in PIEZO1 - vs PIEZO1 + ECs. I Bulk-RNA-seq of saline and BLM (7 days and 14 days) induced mice (n = 3 per group). Gene expression levels were Z-score normalized. P value was calculated using the two-tailed unpaired t-test. J qPCR of Il33 in BLM mouse lung ECs. <t>K</t> <t>IL-33</t> (green) and CD31 (red) co-staining in human IPF vs normal, quantification is shown at right (n = 10). L IL-33 (green) and CD31 (red) co-staining in Yoda1- or GsMTx4-treated fibrotic mouse lungs, quantification is shown at right (n = 3). M IL-33 (green) and CD31 (red)co-staining in Piezo1 WT and Piezo1 ΔEC BLM lungs, quantification is shown at right (n = 3). Error bars represent mean ± SEM, H, K, J, M: two-tailed unpaired t-test; L: one-way ANOVA followed Tukey’s multiple comparwasons test, All n values indicate biologically independent samples. Source data are provided as a Source Data file.
    Human Il 33 Duoset Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+33/Human+IL-33+Quantikine+ELISA+Kit/pmc13004862-358-11-16
    Average 94 stars, based on 1 article reviews
    human il 33 duoset elisa kit - by Bioz Stars, 2026-10
    94/100 stars
      Buy from Supplier

    95
    R&D Systems il 33
    A CellChat analysis of human lung snRNA-seq data. B Venn of 47 shared DEGs from four datasets ( GSE159354 , GSE132771 , GSE128033 , GSE122960 ). C Heatmap of 47-gene expression across cell types. D Correlation analysis (Pearson Correlation) of expression of IGFBP5, IL33, MGP, SPRY1, ACKR1 and mechanical stress scores in ECs. E Correlation analysis (Pearson Correlation) of expression of PIEZO1 and IGFBP5, IL33, MGP, SPRY1, ACKR1 in ECs. F Human snRNA-seq UMAP and violin of IL33 distribution and subpopulations. G Bar chart showed expression of IL33 (mean ± SEM) in IPF (n = 7966 cells) vs control (n = 4174 cells). P value was calculated using the two-tailed unpaired t-test. H Violin of IL33 in PIEZO1 - vs PIEZO1 + ECs. I Bulk-RNA-seq of saline and BLM (7 days and 14 days) induced mice (n = 3 per group). Gene expression levels were Z-score normalized. P value was calculated using the two-tailed unpaired t-test. J qPCR of Il33 in BLM mouse lung ECs. <t>K</t> <t>IL-33</t> (green) and CD31 (red) co-staining in human IPF vs normal, quantification is shown at right (n = 10). L IL-33 (green) and CD31 (red) co-staining in Yoda1- or GsMTx4-treated fibrotic mouse lungs, quantification is shown at right (n = 3). M IL-33 (green) and CD31 (red)co-staining in Piezo1 WT and Piezo1 ΔEC BLM lungs, quantification is shown at right (n = 3). Error bars represent mean ± SEM, H, K, J, M: two-tailed unpaired t-test; L: one-way ANOVA followed Tukey’s multiple comparwasons test, All n values indicate biologically independent samples. Source data are provided as a Source Data file.
    Il 33, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+il+33/Recombinant+Human+IL-33+Protein/10__1042_slash_cs20250686-101-31-38
    Average 95 stars, based on 1 article reviews
    il 33 - by Bioz Stars, 2026-10
    95/100 stars
      Buy from Supplier

    Image Search Results


    Mechanism underlying tumor necrosis factor-like ligand 1A (TL1A)–C-C motif chemokine ligand 8 (CCL8) axis activation in the context of allergic inflammation. (A and B) Expression levels of TL1A induced by different stimuli in human airway epithelial cells or macrophages. (C) TL1A expression in uninduced macrophages, macrophages induced by interleukin 33 (IL-33), and macrophages induced by IL-33 plus interleukin 2 (IL-2). (D and E) Comparison of the expression levels of CCL8 induced by different concentrations of TL1A, quantified using reverse transcription polymerase chain reaction (RT-PCR) or transcriptomic sequencing. The messenger RNA (mRNA) levels of CCL8 after the transfection of TL1A-M plasmids, quantified using RT-PCR (F) or transcriptomic sequencing (G). (H) Death receptor 3 (DR3) knockdown abolished the elevation of CCL8 induced by TL1A stimulation. (I) CCL8 level in CD14 + macrophages treated or not with TL1A. (J) RT-PCR analysis of CCL8 transcript following DR3 small interfering RNA (siRNA) treatment. Representative data from CD14 + cells from a single donor. (K) A schematic for the administration of different signaling pathway inhibitors to investigate the pathways involved in TL1A–CCL8 axis activation (BAY11-7082, a nuclear factor kappa B [NF-κB] inhibitor; LY294002, a phosphoinositide 3-kinase [PI3K inhibitor]; PD98059, an extracellular signal-regulated kinase [ERK] inhibitor; SB203580, a p38 inhibitor; and SP600125, a c-Jun N-terminal kinase [JNK] inhibitor). Data are presented as the mean ± SD of triplicate measurements from at least 3 independent cell culture experiments. For primary human macrophage experiments (I and J), cells were derived from n = 4 healthy donors. * P < 0.05 and ** P < 0.01 compared with the respective groups. All in vitro stimulation and inhibitor treatments were analyzed in a blinded manner.

    Journal: Research

    Article Title: Integrated Single-Cell Profiling Reveals TL1A as a Biomarker and Driver of Type 2 Inflammation via Macrophage-Dependent Immunoregulation in Asthma

    doi: 10.34133/research.1190

    Figure Lengend Snippet: Mechanism underlying tumor necrosis factor-like ligand 1A (TL1A)–C-C motif chemokine ligand 8 (CCL8) axis activation in the context of allergic inflammation. (A and B) Expression levels of TL1A induced by different stimuli in human airway epithelial cells or macrophages. (C) TL1A expression in uninduced macrophages, macrophages induced by interleukin 33 (IL-33), and macrophages induced by IL-33 plus interleukin 2 (IL-2). (D and E) Comparison of the expression levels of CCL8 induced by different concentrations of TL1A, quantified using reverse transcription polymerase chain reaction (RT-PCR) or transcriptomic sequencing. The messenger RNA (mRNA) levels of CCL8 after the transfection of TL1A-M plasmids, quantified using RT-PCR (F) or transcriptomic sequencing (G). (H) Death receptor 3 (DR3) knockdown abolished the elevation of CCL8 induced by TL1A stimulation. (I) CCL8 level in CD14 + macrophages treated or not with TL1A. (J) RT-PCR analysis of CCL8 transcript following DR3 small interfering RNA (siRNA) treatment. Representative data from CD14 + cells from a single donor. (K) A schematic for the administration of different signaling pathway inhibitors to investigate the pathways involved in TL1A–CCL8 axis activation (BAY11-7082, a nuclear factor kappa B [NF-κB] inhibitor; LY294002, a phosphoinositide 3-kinase [PI3K inhibitor]; PD98059, an extracellular signal-regulated kinase [ERK] inhibitor; SB203580, a p38 inhibitor; and SP600125, a c-Jun N-terminal kinase [JNK] inhibitor). Data are presented as the mean ± SD of triplicate measurements from at least 3 independent cell culture experiments. For primary human macrophage experiments (I and J), cells were derived from n = 4 healthy donors. * P < 0.05 and ** P < 0.01 compared with the respective groups. All in vitro stimulation and inhibitor treatments were analyzed in a blinded manner.

    Article Snippet: The recombinant proteins, small-molecular compounds, or inhibitors were purchased as indicated: recombinant mouse IL-13, IL-33, and TSLP protein (MCE); recombinant human IL-2, IL-4, TNF-α, and IFN-γ protein (Abbkine); poly(I:C) (Selleck); lipopolysaccharide (Sigma-Aldrich); IL-1β (Thermo Fisher); and small-molecule inhibitors BAY11-7082, LY294002, PD98059, SB203580, and SP600125 (Selleck).

    Techniques: Activation Assay, Expressing, Comparison, Reverse Transcription, Polymerase Chain Reaction, Reverse Transcription Polymerase Chain Reaction, Sequencing, Transfection, Knockdown, Small Interfering RNA, Cell Culture, Derivative Assay, In Vitro

    A CellChat analysis of human lung snRNA-seq data. B Venn of 47 shared DEGs from four datasets ( GSE159354 , GSE132771 , GSE128033 , GSE122960 ). C Heatmap of 47-gene expression across cell types. D Correlation analysis (Pearson Correlation) of expression of IGFBP5, IL33, MGP, SPRY1, ACKR1 and mechanical stress scores in ECs. E Correlation analysis (Pearson Correlation) of expression of PIEZO1 and IGFBP5, IL33, MGP, SPRY1, ACKR1 in ECs. F Human snRNA-seq UMAP and violin of IL33 distribution and subpopulations. G Bar chart showed expression of IL33 (mean ± SEM) in IPF (n = 7966 cells) vs control (n = 4174 cells). P value was calculated using the two-tailed unpaired t-test. H Violin of IL33 in PIEZO1 - vs PIEZO1 + ECs. I Bulk-RNA-seq of saline and BLM (7 days and 14 days) induced mice (n = 3 per group). Gene expression levels were Z-score normalized. P value was calculated using the two-tailed unpaired t-test. J qPCR of Il33 in BLM mouse lung ECs. K IL-33 (green) and CD31 (red) co-staining in human IPF vs normal, quantification is shown at right (n = 10). L IL-33 (green) and CD31 (red) co-staining in Yoda1- or GsMTx4-treated fibrotic mouse lungs, quantification is shown at right (n = 3). M IL-33 (green) and CD31 (red)co-staining in Piezo1 WT and Piezo1 ΔEC BLM lungs, quantification is shown at right (n = 3). Error bars represent mean ± SEM, H, K, J, M: two-tailed unpaired t-test; L: one-way ANOVA followed Tukey’s multiple comparwasons test, All n values indicate biologically independent samples. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Single-cell multiomics uncovers an endothelial mechanosensitive PIEZO1-IL-33 axis driving pulmonary fibrosis

    doi: 10.1038/s41467-026-70193-w

    Figure Lengend Snippet: A CellChat analysis of human lung snRNA-seq data. B Venn of 47 shared DEGs from four datasets ( GSE159354 , GSE132771 , GSE128033 , GSE122960 ). C Heatmap of 47-gene expression across cell types. D Correlation analysis (Pearson Correlation) of expression of IGFBP5, IL33, MGP, SPRY1, ACKR1 and mechanical stress scores in ECs. E Correlation analysis (Pearson Correlation) of expression of PIEZO1 and IGFBP5, IL33, MGP, SPRY1, ACKR1 in ECs. F Human snRNA-seq UMAP and violin of IL33 distribution and subpopulations. G Bar chart showed expression of IL33 (mean ± SEM) in IPF (n = 7966 cells) vs control (n = 4174 cells). P value was calculated using the two-tailed unpaired t-test. H Violin of IL33 in PIEZO1 - vs PIEZO1 + ECs. I Bulk-RNA-seq of saline and BLM (7 days and 14 days) induced mice (n = 3 per group). Gene expression levels were Z-score normalized. P value was calculated using the two-tailed unpaired t-test. J qPCR of Il33 in BLM mouse lung ECs. K IL-33 (green) and CD31 (red) co-staining in human IPF vs normal, quantification is shown at right (n = 10). L IL-33 (green) and CD31 (red) co-staining in Yoda1- or GsMTx4-treated fibrotic mouse lungs, quantification is shown at right (n = 3). M IL-33 (green) and CD31 (red)co-staining in Piezo1 WT and Piezo1 ΔEC BLM lungs, quantification is shown at right (n = 3). Error bars represent mean ± SEM, H, K, J, M: two-tailed unpaired t-test; L: one-way ANOVA followed Tukey’s multiple comparwasons test, All n values indicate biologically independent samples. Source data are provided as a Source Data file.

    Article Snippet: The amounts of IL-33 in HUVECs supernatant were quantified using the Human IL-33 DuoSet ELISA kit (R&D Systems, #D3300B) according to the manufacturer’s instructions.

    Techniques: Gene Expression, Expressing, Control, Two Tailed Test, RNA Sequencing, Saline, Staining

    A Schematic of BLM-induced fibrosis in Il33 WT vs Il33 ΔEC mice. B Il33 mRNA (n = 4) and IL-33 protein in lung ECs (n = 3). C Representative Masson/PSR images and quantification (n = 5). D αSMA immunofluorescence and quantification (n = 4). E Lung hydroxyproline content (n = 5). F Schematic: EC-specific Il33 overexpression via AAV-Tie1 in Piezo1 WT and Piezo1 ΔEC mice; 4-week pretreatment, BLM at week 4, sacrifice at week 7. G IL-33 expression in ECs, immune and epithelial cells after AAV-OE- Il33 (n = 3). H Masson/PSR images and quantification (n = 5). I αSMA immunofluorescence and quantification (n = 4). J Hydroxyproline content (n = 5). Error bars: mean ± SEM; B,G: two-tailed unpaired t-test; C,D-E,I: two-way ANOVA followed Tukey’s multiple comparisons test; H,J: three-way ANOVA followed Tukey’s multiple comparisons test. All n values indicate biologically independent samples. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Single-cell multiomics uncovers an endothelial mechanosensitive PIEZO1-IL-33 axis driving pulmonary fibrosis

    doi: 10.1038/s41467-026-70193-w

    Figure Lengend Snippet: A Schematic of BLM-induced fibrosis in Il33 WT vs Il33 ΔEC mice. B Il33 mRNA (n = 4) and IL-33 protein in lung ECs (n = 3). C Representative Masson/PSR images and quantification (n = 5). D αSMA immunofluorescence and quantification (n = 4). E Lung hydroxyproline content (n = 5). F Schematic: EC-specific Il33 overexpression via AAV-Tie1 in Piezo1 WT and Piezo1 ΔEC mice; 4-week pretreatment, BLM at week 4, sacrifice at week 7. G IL-33 expression in ECs, immune and epithelial cells after AAV-OE- Il33 (n = 3). H Masson/PSR images and quantification (n = 5). I αSMA immunofluorescence and quantification (n = 4). J Hydroxyproline content (n = 5). Error bars: mean ± SEM; B,G: two-tailed unpaired t-test; C,D-E,I: two-way ANOVA followed Tukey’s multiple comparisons test; H,J: three-way ANOVA followed Tukey’s multiple comparisons test. All n values indicate biologically independent samples. Source data are provided as a Source Data file.

    Article Snippet: The amounts of IL-33 in HUVECs supernatant were quantified using the Human IL-33 DuoSet ELISA kit (R&D Systems, #D3300B) according to the manufacturer’s instructions.

    Techniques: Immunofluorescence, Over Expression, Expressing, Two Tailed Test

    HUVECs under 20% stretch for 0,6,24 h or 2,12,25 kPa substrates; IL-33 secretion ( n = 3) A and mRNA (n = 3) B . C PIEZO1 knock-down with sh PIEZO1 ( n = 3). HUVECs were transduced with sh PIEZO1 for 48 h, cultured on 25 kPa substrates for 24 h or subjected to 6 h mechanical stretch before measuring IL-33 secretion ( n = 3) D and mRNA ( n = 3) E . HUVECs were cultured on 2, 12, 25 kPa substrates for 24 h or stretched (20%) for 0, 6, 24 h, followed by measurement of calpain activity F and CAPN2 protein G ( n = 3). HUVECs (sh PIEZO1 ) were cultured on 25 kPa substrates for 24 h or subjected to 6 h mechanical stretch, followed by measurement of calpain activity ( n = 3) H and CAPN2 protein levels ( n = 3) I . J CAPN2 knock-down with shCAPN2 ( n = 3). K HUVECs (sh CAPN2 ) were cultured on 25 kPa substrates for 24 h or subjected to 6 h mechanical stretch, IL-33 secretion(left) and mRNA(right) ( n = 3). L Model for paracrine IL-33 regulation. M Cistrome: STAT3 predicted to drive IL-33 regulation. N intersection of top 100 motifs in BLM-treated mouse ECs with top 10 TFs. O The protein levels of P-STAT3 and STAT3 in HUVECs treated with 20% stretch for 0 and 6 hours ( n = 3). P The protein levels of P-STAT3 and STAT3 in HUVECs (sh PIEZO1 or sh CAPN2 ) treated with 20% stretch for 6 h ( n = 3). Q STAT3 knock-down with sh STAT3 ( n = 3). R HUVECs (sh STAT3 ) were cultured on 25 kPa substrates for 24 h or subjected to 6 h mechanical stretch; IL-33 secretion(left) and mRNA(right) ( n = 3). Error bars: mean ± SEM; C , G , J , O – Q : two-tailed unpaired t-test; A , B , F : one-way ANOVA followed Šídák’s multiple comparisons test, D – E , H – I , K , R : two-way ANOVA Tukey’s multiple comparisons test. All n denote biologically independent samples. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Single-cell multiomics uncovers an endothelial mechanosensitive PIEZO1-IL-33 axis driving pulmonary fibrosis

    doi: 10.1038/s41467-026-70193-w

    Figure Lengend Snippet: HUVECs under 20% stretch for 0,6,24 h or 2,12,25 kPa substrates; IL-33 secretion ( n = 3) A and mRNA (n = 3) B . C PIEZO1 knock-down with sh PIEZO1 ( n = 3). HUVECs were transduced with sh PIEZO1 for 48 h, cultured on 25 kPa substrates for 24 h or subjected to 6 h mechanical stretch before measuring IL-33 secretion ( n = 3) D and mRNA ( n = 3) E . HUVECs were cultured on 2, 12, 25 kPa substrates for 24 h or stretched (20%) for 0, 6, 24 h, followed by measurement of calpain activity F and CAPN2 protein G ( n = 3). HUVECs (sh PIEZO1 ) were cultured on 25 kPa substrates for 24 h or subjected to 6 h mechanical stretch, followed by measurement of calpain activity ( n = 3) H and CAPN2 protein levels ( n = 3) I . J CAPN2 knock-down with shCAPN2 ( n = 3). K HUVECs (sh CAPN2 ) were cultured on 25 kPa substrates for 24 h or subjected to 6 h mechanical stretch, IL-33 secretion(left) and mRNA(right) ( n = 3). L Model for paracrine IL-33 regulation. M Cistrome: STAT3 predicted to drive IL-33 regulation. N intersection of top 100 motifs in BLM-treated mouse ECs with top 10 TFs. O The protein levels of P-STAT3 and STAT3 in HUVECs treated with 20% stretch for 0 and 6 hours ( n = 3). P The protein levels of P-STAT3 and STAT3 in HUVECs (sh PIEZO1 or sh CAPN2 ) treated with 20% stretch for 6 h ( n = 3). Q STAT3 knock-down with sh STAT3 ( n = 3). R HUVECs (sh STAT3 ) were cultured on 25 kPa substrates for 24 h or subjected to 6 h mechanical stretch; IL-33 secretion(left) and mRNA(right) ( n = 3). Error bars: mean ± SEM; C , G , J , O – Q : two-tailed unpaired t-test; A , B , F : one-way ANOVA followed Šídák’s multiple comparisons test, D – E , H – I , K , R : two-way ANOVA Tukey’s multiple comparisons test. All n denote biologically independent samples. Source data are provided as a Source Data file.

    Article Snippet: The amounts of IL-33 in HUVECs supernatant were quantified using the Human IL-33 DuoSet ELISA kit (R&D Systems, #D3300B) according to the manufacturer’s instructions.

    Techniques: Knockdown, Transduction, Cell Culture, Activity Assay, Two Tailed Test